Germantown, Maryland, U.S., September 21, 2026
Precigen has announced that the U.S. Food and Drug Administration (FDA) has granted Platform Technology Designation to its AdenoVerse™ platform, a proprietary gene delivery technology designed to support the development of next-generation genetic medicines. The designation represents a regulatory milestone for Precigen as the company advances its gene therapy pipeline and seeks to leverage a common technology platform across multiple therapeutic programs. The FDA’s Platform Technology Designation program is intended to facilitate the development and review of biological products that incorporate designated platform technologies by allowing certain validated platform information to potentially be leveraged across subsequent applications. For Precigen, the designation recognizes the regulatory relevance of the AdenoVerse platform and could support more efficient development of future gene therapy candidates that use the technology. The designation itself does not constitute approval of any individual therapy or establish clinical efficacy.
AdenoVerse Supports Gene Therapy Development
The AdenoVerse platform is based on a proprietary adenoviral vector technology intended to deliver therapeutic genetic material to target cells. Precigen has developed the platform as part of its broader strategy to create gene therapies and genetic medicines for serious diseases. Adenoviral vectors can be engineered to carry therapeutic genes into cells, making vector design, tissue targeting, payload delivery and manufacturing important components of successful gene therapy development. Precigen’s platform is designed to address these elements through a standardized technological foundation that can potentially be adapted across different therapeutic programs.
The FDA designation is significant because platform technologies can play an important role in reducing repetitive development work when the same underlying technology is incorporated into multiple biological products. Under the FDA’s platform technology framework, a designated platform may allow certain information regarding manufacturing processes, analytical methods or other aspects of the technology to be referenced or leveraged in subsequent regulatory submissions when applicable requirements are met. This approach can potentially help developers streamline aspects of CMC development and regulatory review while maintaining appropriate product-specific evaluation.
FDA Designation Strengthens Regulatory Strategy
Advertisement
Precigen said the FDA Platform Technology Designation represents recognition of the AdenoVerse platform’s potential utility across its development pipeline. The designation is particularly relevant to the company’s efforts to develop multiple genetic medicines using a shared technological foundation. By establishing regulatory information around the platform, Precigen may be able to use certain previously reviewed information in future development programs, subject to FDA requirements and the specific characteristics of each product. The regulatory milestone also highlights the growing importance of platform-based approaches to gene therapy development. Rather than developing every vector and manufacturing process independently, biotechnology companies increasingly seek technologies that can be adapted across multiple indications. A validated platform can potentially support greater consistency in development, manufacturing and regulatory processes. However, each individual gene therapy remains subject to its own clinical, safety, efficacy, manufacturing and regulatory requirements.
Precigen Advances Genetic Medicine Pipeline
Precigen is developing a pipeline of genetic medicines and gene therapies designed to address serious diseases. The AdenoVerse platform forms part of the company’s technology infrastructure for developing these therapies. The FDA designation could become particularly valuable as additional candidates using the platform progress through preclinical research, IND-enabling studies and clinical development. For cGxP.wire readers, the announcement highlights important developments in gene therapy, viral-vector technology, regulatory science, platform technologies and biopharmaceutical development. The FDA designation demonstrates how regulators and biotechnology companies are working to establish more efficient pathways for technologies that may be used across multiple biological products.
At the same time, the designation should be distinguished from an FDA approval: AdenoVerse itself is not a marketed therapy, and individual products incorporating the platform will still require appropriate regulatory review. The milestone gives Precigen an additional regulatory foundation as it advances its broader genetic medicine strategy. Future clinical and regulatory progress will determine how extensively the AdenoVerse platform can be applied across the company’s pipeline and whether it can support the development of additional gene therapy products.
Source: Precigen press release
